How feasible is a cage-free solution for de novo coronary artery disease?
- PMID: 39236725
- DOI: 10.1016/S0140-6736(24)01696-9
How feasible is a cage-free solution for de novo coronary artery disease?
Conflict of interest statement
MBM reports honoraria from Boston Scientific partly related to the subject of the current Comment. AJK reports research grants and consulting or speakers fees paid to their institution (Columbia University or Cardiovascular Research Foundation) from Medtronic, Boston Scientific, Abbott Vascular, Amgen, CathWorks, Concept Medical, Philips, ReCor Medical, Neurotronic, Biotronik, Chiesi, Bolt Medical, Magenta Medical, SoniVie, and Shockwave Medical. AJK also has stock options in Bolt Medical and has received travel expenses and meals from Amgen, Medtronic, Biotronik, Boston Scientific, Abbott Vascular, CathWorks, Concept Medical, Novartis, Philips, Abiomed, ReCor Medical, Chiesi, Zoll, Shockwave, and Regeneron.
Comment on
-
Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.Lancet. 2024 Sep 14;404(10457):1040-1050. doi: 10.1016/S0140-6736(24)01594-0. Epub 2024 Sep 2. Lancet. 2024. PMID: 39236727 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
